Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?

ACS Chem Neurosci. 2017 Apr 19;8(4):702-711. doi: 10.1021/acschemneuro.7b00034. Epub 2017 Mar 3.

Abstract

In 1967, L-dopa was introduced as part of the pharmacological therapy of Parkinson's disease (PD) and, in spite of extensive research, no additional effective drugs have been discovered to treat PD. This brings forward the question: why have no new drugs been developed? We consider that one of the problems preventing the discovery of new drugs is that we still have no information on the pathophysiology of the neurodegeneration of the neuromelanin-containing nigrostriatal dopaminergic neurons. Currently, it is widely accepted that the degeneration of dopaminergic neurons, i.e., in the substantia nigra pars compacta, involves mitochondrial dysfunction, the formation of neurotoxic oligomers of alpha-synuclein, the dysfunction of protein degradation systems, neuroinflammation, and oxidative and endoplasmic reticulum stress. However, the initial trigger of these mechanisms in the nigrostriatal system is still unknown. It has been reported that aminochrome induces the majority of these mechanisms involved in the neurodegeneration process. Aminochrome is formed within the cytoplasm of neuromelanin-containing dopaminergic neurons during the oxidation of dopamine to neuromelanin. The oxidation of dopamine to neuromelanin is a normal and harmless process, because healthy individuals have intact neuromelanin-containing dopaminergic neurons. Interestingly, aminochrome-induced neurotoxicity is prevented by two enzymes: DT-diaphorase and glutathione transferase M2-2, which explains why melanin-containing dopaminergic neurons are intact in healthy human brains.

Keywords: Neurodegeneration; alpha-synuclein; astrocytes; autophagy dysfunction; endoplasmic reticulum stress; mitochondria dysfunction; neuroinflammation; proteasome dysfunction.

Publication types

  • Review

MeSH terms

  • Animals
  • Dopamine / metabolism*
  • Dopaminergic Neurons / metabolism
  • Dopaminergic Neurons / pathology*
  • Humans
  • Melanins / metabolism
  • Nerve Degeneration / metabolism*
  • Nerve Degeneration / physiopathology
  • Oxidation-Reduction
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology*
  • Parkinson Disease / physiopathology
  • Pars Compacta / metabolism
  • Pars Compacta / pathology*
  • Pars Compacta / physiopathology

Substances

  • Melanins
  • neuromelanin
  • Dopamine